Catalent - CTLT Stock Forecast, Price & News

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent Stock Performance

CTLT Stock traded up $0.02 during midday trading on Friday, reaching $109.96. The company had a trading volume of 26,880 shares, compared to its average volume of 968,685. The stock has a 50 day moving average price of $107.67 and a 200 day moving average price of $103.23. The firm has a market capitalization of $19.71 billion, a PE ratio of 39.83, a P/E/G ratio of 1.72 and a beta of 1.28. The company has a quick ratio of 2.25, a current ratio of 2.89 and a debt-to-equity ratio of 0.90. Catalent has a fifty-two week low of $86.34 and a fifty-two week high of $142.64.

Insider Buying and Selling

In other Catalent news, SVP Kay A. Schmidt sold 323 shares of Catalent stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total transaction of $34,528.70. Following the transaction, the senior vice president now directly owns 13,455 shares in the company, valued at approximately $1,438,339.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Catalent news, SVP Kay A. Schmidt sold 323 shares of the business's stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total transaction of $34,528.70. Following the completion of the transaction, the senior vice president now owns 13,455 shares of the company's stock, valued at approximately $1,438,339.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ricky Hopson sold 312 shares of the business's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $106.90, for a total transaction of $33,352.80. Following the transaction, the insider now directly owns 17,035 shares of the company's stock, valued at approximately $1,821,041.50. The disclosure for this sale can be found here. Insiders have sold a total of 4,462 shares of company stock valued at $476,951 over the last quarter. Corporate insiders own 0.53% of the company's stock.